From Molecule to Market: An Integrated CRDMO Approach for Peptides & Oligonucleotides
- Peptide and oligonucleotide therapeutics increasingly present challenges related to molecular complexity, developability, and global regulatory expectations
- Describing an end-to-end CRDMO approach, supporting programs from early discovery and research through CMC development, process scale-up, GMP manufacturing, and commercial supply.
- Drawing on Hybio’s practical global experience across the full development lifecycle, the talk will highlight how early technical and developability considerations can be integrated with downstream manufacturing strategies to enable robust, scalable, and compliant production of complex peptide therapeutics, while de-risking development timelines and supporting successful global commercialization